Plasma exchange became popular in the treatment of Guillain-Barre syndrome with the publication in 1985 of results by the Guillain-Barre Study Group. Since then we have treated 24 patients referred for plasma exchange. We have audited their outcome and compared this with the results of patients in the treatment arm of the USA Study. Our patients were of comparable age and clinical severity and had similar duration of illness before starting plasma exchange. Nine ofour patients required ventilation for a median of 24 days. The median time to improve one clinical grade was 19 days which compared well with the Study Group results. We have shown that plasma exchange may be safely performed in a district general hospital in a setting appropriate to the patient's clinical condition. We concur with the central conclusion of the Study, that if treatment is started early in the disease, the patient's outcome is improved.
Introduction
Guillain-Barre syndrome is an acute inflammatory demyelinating neuropathy whose aetiology is incompletely understood. ' The incidence has been estimated at 1.9 per 100,000.2 Plasma exchange has been used in the treatment ofthis condition because ofevidence ofa circulating plasma factor, probably antibody toxic to peripheral nerve myelin.3 Results were initially mixed4'5 but the role of plasma exchange was established by the Guillain-Barre Syndrome Study Group in North America.6 This demonstrated a marked beneficial effect especially if plasma exchange was carried out early in the disease. In this paper we report our own experience and results in 30 patients referred for plasma exchange to a hospital which provides this service on a supra-district basis.
Patients
Patients were drawn from a population of 1.5 million. Between January 1985 and August 1988, 30 patients with a diagnosis of Guillain-Barre syndrome were referred for consideration of plasma exchange. The patients were seen by a consultant neurologist (ITF) to confirm the diagnosis, and to grade patients clinically using the criteria of the Guillain-Barre Study Group;6 grading details are shown in Table I . Patients received plasma exchange if they were clinically Grade 4 or 5 or were deteriorating. Twenty-four patients were treated and data are available on 22 of these. Patient details are described in Table II . Bed-bound Grade 5 Requiring assisted ventilation for at least part of the day Grade 6 Dead complication and relapse rates and few problems directly attributable to the procedure. Hyponatraemia was not reported by the USA study but has been described as a complication of Guillain-Barre syndrome.'" Poor blood flow rates through venous cannulae associated with clinical dehydration were common early in the course of treatment, and we have also found patients with initial high haemoglobin levels which fell during the course of treatment without apparent blood loss. We postulate that both ofthese problems may be the result of initial haemoconcentration which was corrected during the hospital treatment. Plasma exchange can be safely performed in a district general hospital in the clinical setting appropriate to the patient's condition, either a general medical ward or intensive care unit. We would emphasize the central conclusion of the Guillain-Barre Syndrome Study Group: that patients who are clinical grade 3 or worse or who are deteriorating should be offered plasma exchange. This should be started as early as possible in the disease.
